The Leslie & Susan Gonda (Goldschmied) Diabetes & Genetic Research Center’s Endocrinology Program is developing an international reputation for excellence in endocrinology research and treatment.
Some of the major research initiatives under way in the program include:
The Endocrinology Program provides high-quality comprehensive endocrine care for patients undergoing treatment for non-endocrine cancers. Issues addressed include:
- Investigation of endocrine complications as a result of chemotherapy, radiation therapy and bone marrow transplant in cancer patients.
- Management of immunosuppressive therapy-related endocrine complications.
- Development of clinical practice guidelines for the management of hypothalamic-pituitary endocrine complications after bone marrow transplant.
- Aggressive prevention and treatment of bone marrow transplant osteoporosis in both men and women.
After thyroid cancer surgery, standard treatment consists of radioiodine to ablate residual tumor cells. However, we have been exploring methods of augmenting or supplanting this therapy. Initiatives include:
- Continued clinical research in thyroid cancer exploring new diagnostic and therapeutic alternatives to radioactive iodine therapy
- Providing compassionate use of recombinant human thyroid stimulating hormone (Thyrogen) for thyroid cancer therapy
These tumors present a significant challenge both at diagnosis and in treatment. Research efforts include:
- Advancing the management of neuroendocrine tumors with the use of radioactive iodine MIBG
- Management of male and female sexual dysfunction in premature gonadal/ovarian failure patients
- Clinical research in male sexual dysfunction in patients with cancer and diabetes